Advertisement
Advertisement
RNXT
RenovoRx, Inc. Common Stock
1.00
USDSponsored
+0.05
+4.85%
Feb 06, 15:58 UTC -5
Closed
After-Market
1.00
0.00
+0.30%
RNXT Earnings Reports
Positive Surprise Ratio
RNXT beat 11 of 17 last estimates.
65%
Next Report
Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
$456.28K
/-$0.08
Implied change from Q3 25 (Revenue/ EPS)
+71.53%
/--
Implied change from Q4 24 (Revenue/ EPS)
+961.11%
/-38.46%
RenovoRx, Inc. Common Stock earnings per share and revenue
On Nov 13, 2025, RNXT reported earnings of -0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.08 USD, resulting in a 1.96% surprise. Revenue reached 266.00 thousand, compared to an expected 413.44 thousand, with a -35.66% difference. The market reacted with a -23.03% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 456.28 thousand USD, implying an increase of 0.00% EPS, and increase of 71.53% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were RenovoRx, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, RenovoRx, Inc. Common Stock reported EPS of -$0.08, beating estimates by 1.96%, and revenue of $266.00K, -35.66% below expectations.
How did the market react to RenovoRx, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -23.03%, changed from $0.97 before the earnings release to $0.75 the day after.
When is RenovoRx, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for RenovoRx, Inc. Common Stock's next earnings report?
Based on 6
analysts, RenovoRx, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $456.28K for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement